GBLX - GB Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1420
-0.0019 (-1.32%)
At close: 3:53PM EDT
Stock chart is not supported by your current browser
Previous Close0.1439
Open0.1400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1400 - 0.1500
52 Week Range0.1300 - 0.5100
Volume90,750
Avg. Volume551,125
Market Cap34.747M
Beta (3Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)-0.1510
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
    CNW Group7 days ago

    GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients

    GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients

  • GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
    PR Newswire21 days ago

    GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies

    OTTAWA, Ontario, May 28, 2019 /PRNewswire/ -- GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (GBLX), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in collaboration with the National Research Council ("NRC") Canada under the direction of Dr. Lee Ellis at NRC laboratories in Halifax, Nova Scotia. Growing public and government concerns regarding opioid abuse make novel pain treatments a promising field of research and development.

  • GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility
    PR Newswirelast month

    GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility

    Positioned to Increase Revenue by Approximately $5.6 Million LAS VEGAS , May 14, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) today announced it is nearing completion of $700,000 in power and water ...

  • GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center
    PR Newswire2 months ago

    GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center

    Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients. LAS VEGAS, April 16, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), a partner in GB Sciences Louisiana, LLC, is announcing that all cultivation operations at LSU Agricultural Center are now open. This will allow a continuous harvest for patients by increasing GB Sciences Louisiana's production capacity 500%.

  • Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times
    PR Newswire3 months ago

    Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times

    LAS VEGAS, April 2, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis Conference TODAY, April 2, at 4:40pm. Learn more here.

  • GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients
    PR Newswire3 months ago

    GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients

    LAS VEGAS, March 28, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced results from a new study that shows only three chemical varieties of cannabis were sold in the Nevada dispensaries between January 2016 and June 2017-- despite nearly 400 different "strain names" appearing on product packaging. Co-authored by GB Sciences, Chaminade University, Makai Biotechnology and Digipath Labs, and published in the journal Cannabis and Cannabinoid Research, the study reveals extremely low chemical diversity within the cannabis varieties sold in the Nevada market during its medical-only phase.

  • In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility
    PR Newswire3 months ago

    In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility

    With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS, March 26, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced that The LSU Agricultural Center (AgCenter) received confirmation from the Louisiana Department of Agriculture and Forestry (LDAF) that GB Sciences Louisiana is deemed suitable for full-scale operations.

  • Louisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Production Facility
    PR Newswire3 months ago

    Louisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Production Facility

    With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS, March 22, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced that The LSU Agricultural Center (AgCenter) received confirmation from the Louisiana Department of Agriculture and Forestry (LDAF) that GB Sciences Louisiana is deemed suitable for full-scale operations.

  • GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.
    PR Newswire3 months ago

    GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

    Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy LAS VEGAS , March 19, 2019 /PRNewswire/ ...

  • GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue
    PR Newswire3 months ago

    GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue

    LSU AgCenter issued the following statement on Friday, March 8th. LAS VEGAS , March 12, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that the Louisiana State University Agricultural Center ...

  • Market Exclusive5 months ago

    GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center

    In November last year, GB Sciences Inc. (OTCMKTS:GBLX) agreed to work together with Louisiana State University Agricultural Center focusing on cannabis. Notably, the two institutions would cooperate in research and development on cannabis with a keen eye on its therapeutic properties. The partnership has hit the first milestone with the maiden harvesting of cannabis. Leveraging […] The post GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center appeared first on Market Exclusive.

  • GB Sciences Declares A "Research Revolution" At Its "2018 Innovation In Medical Cannabis Therapies" Symposium
    PR Newswire6 months ago

    GB Sciences Declares A "Research Revolution" At Its "2018 Innovation In Medical Cannabis Therapies" Symposium

    On November 9th, GB Sciences hosted an open mic-dialogue with key stakeholders in the cannabis industry that focused on addressing medical patients' needs through improved standardization and innovation of future medical cannabis products. LAS VEGAS, Dec. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces the success of its first annual, "Innovation in Medical Cannabis Therapies" (IMCT) Symposium, held on Friday, November 9th at the "Keep Memory Alive" Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Throughout the day's program, there was an emerging sense of heightened responsibility on the part of the cannabis industry to better address medical cannabis patients' needs through research and development of medical cannabis products that are better standardized, more easily-dosed, and made more widely-available to cannabis patients at a fair price.

  • GB Sciences and The Colorado Hemp Project Sell First Hemp Crop for $0.7 Million Dollars
    PR Newswire6 months ago

    GB Sciences and The Colorado Hemp Project Sell First Hemp Crop for $0.7 Million Dollars

    LAS VEGAS, Dec. 12, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that their first crop in the rapidly expanding hemp market expects to yield a gross profit of $0.7million dollars as well as seeds and genetics.  These seeds and genetic information will provide the mother plants in order to expand the program, which should prove to be a significant revenue generator for the Company. An integral part of the Company's success is its partnership with The Colorado Hemp Project (CHP). "GB Sciences told us what they wanted out of the plants, and we worked together to fill in the blanks," remarked Wild Bill.

  • Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer, Introduces, "Unique Methods to Identify Strong Lead Compounds" at the International Cannabinoid Derived Pharmaceutical Summit
    PR Newswire6 months ago

    Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer, Introduces, "Unique Methods to Identify Strong Lead Compounds" at the International Cannabinoid Derived Pharmaceutical Summit

    Dr. Small-Howard will elucidate GB Sciences' Natural Products-Based Approach to Drug Discovery and is a panelist for the "Welcome Panel Session: Bringing Together Industry and Academia". LAS ...

  • GB Sciences and Louisiana State University Agricultural Center Enter a Joint Research and Development Agreement for the Production of Therapeutic Cannabis Targeting Severe Medical Conditions and Diseases
    PR Newswire6 months ago

    GB Sciences and Louisiana State University Agricultural Center Enter a Joint Research and Development Agreement for the Production of Therapeutic Cannabis Targeting Severe Medical Conditions and Diseases

    LAS VEGAS, Dec. 7, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State University Agricultural Center, entered into a Master Research and Development Agreement with GB Sciences Louisiana, LLC. The Master Research and Development Agreement comes from the parties' desire to participate in joint research and development projects arising out of the production of therapeutic cannabis in Louisiana. As a public institution of higher education, the LSU AgCenter's public-private partnership with GB Sciences Louisiana represents a first in the therapeutic cannabis industry.

  • GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor
    PR Newswire7 months ago

    GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor

    Pioneering new scientific research in the publication, Channels, explains the promise of targeting the ionotropic cannabinoid receptor TRPV1, for the treatment and reversal of heart failure. LAS VEGAS, Nov. 27, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed journal Channels, which explains the potential medical benefits of using cannabinoid receptor-targeting therapies for the treatment of heart disease. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including University of Hawaii faculty member and President of Makai Biotechnology, LLC, Dr. Alexander Stokes, and researchers from the University of Kyoto, Japan.

  • GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles
    PR Newswire7 months ago

    GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles

    LAS VEGAS, Nov. 20, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and the Universidad de Sevilla (USE) announce the filing of a provisional patent application on the creation of myrcene-containing nanoparticles for use in the treatment of neuropathic pain. "We have achieved a significant research milestone in the creation of the myrcene-containing nanoparticles that are at the core of our patent-pending, myrcene-based complex mixtures for the treatment of neuropathic pain," said Dr. Andrea Small-Howard.

  • More From Meredith Patterson, GB Sciences' Brain Nurse, As She Examines the Workings of CBD
    PR Newswire7 months ago

    More From Meredith Patterson, GB Sciences' Brain Nurse, As She Examines the Workings of CBD

    Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences. LAS VEGAS, Nov. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) offers a series of blogs by "the brain nurse", Meredith Patterson RN, BSN, CRRN.  In her over 25yrs of experience in neuroscience nursing, Meredith has always paid close attention to her patients.

  • GB Sciences Expands into the Oklahoma Medical Cannabis Market
    PR Newswire7 months ago

    GB Sciences Expands into the Oklahoma Medical Cannabis Market

    LAS VEGAS, Nov. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is proud to announce that it has signed a binding letter of intent with 4EVERGRN, LLC in Oklahoma.  This company has been awarded cultivation, processing and dispensary licenses by the Oklahoma Medical Marijuana Authority. Under their agreement, GB Sciences will design a cultivation and processing facility in Oklahoma, and provide 4EVERGRN with best-practice operating procedures. 4EVERGRN will produce and distribute GB Sciences products and brands under a licensing agreement in exchange for a royalty to GB Sciences.  The agreement can be terminated if quality standards are abridged or compromised.

  • Meredith Patterson, GB Sciences' Brain Nurse, Examines the Workings of CBD
    PR Newswire7 months ago

    Meredith Patterson, GB Sciences' Brain Nurse, Examines the Workings of CBD

    Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences. LAS VEGAS, Nov. 6, 2018 /PR Newswire/-- GB Sciences, Inc. (GBLX) offers a series of blogs by "the brain nurse", Meredith Patterson RN, BSN, CRRN.  In her over 25yrs of experience in neuroscience nursing, Meredith has always paid close attention to her patients.

  • GB Sciences Sponsors "2018 Innovation In Medical Cannabis Therapies" Symposium
    PR Newswire8 months ago

    GB Sciences Sponsors "2018 Innovation In Medical Cannabis Therapies" Symposium

    On November 9th, an international medical cannabis symposium, led by Dr. Andrea Small-Howard, will be held in Las Vegas, NV. LAS VEGAS, Nov. 1, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces sponsorship of a one day, November 9th, international medical cannabis symposium, "Innovation in Medical Cannabis Therapies", under the direction of Dr. Andrea Small-Howard, Chief Science Officer and a member of the Board of Directors for GB Sciences.

  • GB Sciences' Brain Nurse Explores the New and Exciting World of Medical Cannabis
    PR Newswire8 months ago

    GB Sciences' Brain Nurse Explores the New and Exciting World of Medical Cannabis

    Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences. LAS VEGAS, Oct. 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) introduces "the brain nurse", Meredith Patterson RN, BSN, CRRN.  In her over 25yrs of experience in neuroscience nursing, Meredith has learned the value of questions.  When she first heard patients extolling the virtues of cannabis for serious medical conditions, such as Parkinson's as well as difficult to treat ongoing conditions such as chronic pain, she got curious.

  • GB Sciences Harvests the First Hemp Crop in Colorado
    PR Newswire8 months ago

    GB Sciences Harvests the First Hemp Crop in Colorado

    Harvesting the first crop, in association with the Colorado Hemp Project, GB Sciences explores hemp as a highly reliable source of hard to find cannabinoids and terpenes for cannabis-based medical formulations as well as a fresh source of revenue from the sale of hemp oil and related products. LAS VEGAS, Oct. 16, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces the harvesting of its first hemp crop in association with the Colorado Hemp Project. Following closely on the overall philosophy and strategy of the Company, hemp is planned to provide both a reliable source of hard to find cannabinoids and terpenes necessary to manufacture cannabis-based medical formulations and also provide a fresh revenue source through the sale of bulk hemp oil and other hemp related products.